Benitec Biopharma Inc. Common Stock(BNTC)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$11.18
- 52-Week Range
- $9.85 – $17.10
- YTD
- -11.16%
- IV Rank (30D)
- 49.99
- Straddle Price
- $4.90
- P/C Vol Ratio
- 0.13
- Market Cap
- $0.4B
Fair Value
+1.6% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 10.01% |
| Volatility Risk Premium | +141.5pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -26.7% |
| Book / Price | 38.3% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $11.75 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $11.04 |
| Bollinger Width / SMA20 | 143.4% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $0B |
Peers used for multiples: BMRN, CRSP, VCYT
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$11.35
Current Price
$11.18
Deviation
+1.6%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $11.35 | 100% | median 2.7× · 3 peers |
| Peer P/S | n/a | 0% | median 7.1× · 3 peers |
| Market Anchor (SMA50) | $11.75 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.4B
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +2.65% | 11 |
| Feb | +7.87% | 11 |
| Mar | +3.75% | 11 |
| Apr | +10.01% | 11 |
| May | -5.15% | 11 |
| Jun | -11.11% | 11 |
| Jul | +8.15% | 10 |
| Aug | -2.38% | 11 |
| Sep | -10.49% | 11 |
| Oct | -2.36% | 11 |
| Nov | +59.55% | 11 |
| Dec | -3.87% | 11 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $11.01
SMA 50: $11.76
SMA 200: $12.59
Current: $11.18
EMA 12: $10.93
EMA 26: $11.19
MACD: -0.2640 | Signal: 0.0327
BEARISH
ADX (14): 12.37
RANGE
+DI: 20.43
−DI: 19.93
Momentum Oscillators
RSI (14): 49.67
NEUTRAL
Stoch %K: 40.58
Stoch %D: 30.57
Williams %R: -41.15
Volume & Volatility
BB Upper: $11.81
BB Lower: $10.21
NEUTRAL
OBV: -1,720,654
Vol SMA 20: 82,160
Vol ROC: -10.48%
ATR: $0.65
True Range: $0.35
HV 20: 56.0%
HV 30: 48.9%
HV 60: 52.0%
Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:27.356000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
5 of 5 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-05-14 | Pre-Market | 16.87% | 5.35% | 0.32x | Within |
| 2025-09-22 | Pre-Market | 39.03% | 0.45% | 0.01x | Within |
| 2025-11-14 | Pre-Market | 38.95% | 2.02% | 0.05x | Within |
| 2026-02-12 | Pre-Market | 21.33% | 2.82% | 0.13x | Within |
| 2026-05-14 | Pre-Market | 24.46% | 1.53% | 0.06x | Within |
Options Activity
- IV Rank (30D)
- 49.99
- IV Rank (7D)
- 100
- Avg IV
- 184.6%
- Straddle (30D)
- $4.90
- Straddle (7D)
- $4.75
- P/C Volume
- 0.13
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.55
- Correlation (SPY)
- 31.5%
- R²
- 0.10
- Ann. Volatility
- 60.7%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 43,271,817 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Insider Activity
Latest: 2026-05-28
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-28 | David Matthew Friedman | Director | Grant (A) | +35,000 opt | — | EDGAR | |
| 2026-01-26 | Sharon Mates | Director | Grant (A) | +31,500 opt | — | EDGAR | |
| 2025-12-29 | Aaron Cowen | 10%+ Owner | Buy (P) | +576,892 | $13.20 | $7.61M | EDGAR |
| 2025-12-22 | Averill Madison Master Fund, Ltd. | Director | Buy (P) | +184,564 | $11.68 | $2.16M | EDGAR |
| 2025-12-03 | Edward F Smith | Director | Grant (A) | +35,000 opt | — | EDGAR | |
| 2025-12-03 | Peter Francis | Director | Grant (A) | +35,000 opt | — | EDGAR | |
| 2025-12-03 | J KEVIN BUCHI | Director | Grant (A) | +35,000 opt | — | EDGAR | |
| 2025-12-03 | Kishan Mehta | Director | Grant (A) | +35,000 opt | — | EDGAR | |
| 2025-12-03 | Sharon Mates | Director | Grant (A) | +3,500 opt | — | EDGAR | |
| 2025-11-20 | Sophie Mukadam | Chief Operating Officer | Grant (A) | +500,000 opt | — | EDGAR | |
| 2025-11-20 | Megan Boston | Chief Financial Officer | Grant (A) | +200,000 opt | — | EDGAR | |
| 2025-11-20 | Jerel A. Banks | Chief Executive Officer | Grant (A) | +450,000 opt | — | EDGAR | |
| 2025-11-10 | Averill Madison Master Fund, Ltd. | Director | Buy (P) | +5,925,924 | $13.50 | $80.00M | EDGAR |
| 2025-11-07 | Sharon Mates | Director | Grant (A) | +28,517 opt | — | EDGAR | |
| 2025-04-02 | Averill Madison Master Fund, Ltd. | Director | Buy (P) | +65,988 | $12.83 | $846.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
6 insiders · @ $11.18
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Averill Madison Master Fund, Ltd. | Director | 9,546,875 | $106.73M | $83.00M | 3 | 2025-12-22 |
| 2 | SUVRETTA CAPITAL MANAGEMENT, LLC | Director | 8,793,245 | $98.31M | $50.58M | 4 | 2025-03-28 |
| 3 | Aaron Cowen | 10%+ Owner | 1,836,569 | $20.53M | $9.23M | 2 | 2025-12-29 |
| 4 | Steven Michael Oliveira | 10%+ Owner | 951,500 | $10.64M | $1.50M | 1 | 2021-12-09 |
| 5 | J KEVIN BUCHI | Director | 103,910 | $1.16M | $0 | 9 | 2025-12-03 |
| 6 | Megan Boston | Chief Financial Officer | 25,927 | $289.9K | $0 | 6 | 2025-11-20 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 2.1 |
| EV/EBITDA | -3.6 |
| TTM Net Income | $-0.0B |
| TTM EPS | $-1.14 |
| ROE | -26.7% |